PAUL ANTHONY WENDER

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging
    Elena A Goun
    Stanford University, Department of Chemistry Stanford, CA 94305, USA
    Chembiochem 7:1497-515. 2006
  2. ncbi request reprint Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:5299-302. 2006
  3. pmc Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
    Elena A Dubikovskaya
    Department of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305 5080, USA
    Proc Natl Acad Sci U S A 105:12128-33. 2008
  4. pmc "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo
    Brian A DeChristopher
    Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305 5080
    Oncotarget 3:58-66. 2012
  5. ncbi request reprint Toward the ideal synthesis and molecular function through synthesis-informed design
    Paul A Wender
    Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, CA 94305, USA
    Nat Prod Rep 31:433-40. 2014
  6. doi request reprint Rhodium dinaphthocyclooctatetraene complexes: synthesis, characterization and catalytic activity in [5+2] cycloadditions
    Paul A Wender
    Department of Chemistry, Stanford University, CA 94305 5080, USA
    Angew Chem Int Ed Engl 51:2736-40. 2012
  7. ncbi request reprint Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:1893-6. 2006
  8. ncbi request reprint Total synthesis and biological evaluation of 11-desmethyllaulimalide, a highly potent simplified laulimalide analogue
    Paul A Wender
    Departments of Chemistry and Molecular Pharmacology, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:1507-10. 2006
  9. ncbi request reprint Metal-catalyzed [2+2+1] cycloadditions of 1,3-dienes, allenes, and CO
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305 5080, USA
    Angew Chem Int Ed Engl 45:2459-62. 2006
  10. ncbi request reprint Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305, USA
    Curr Drug Discov Technol 1:1-11. 2004

Collaborators

Detail Information

Publications67

  1. ncbi request reprint Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging
    Elena A Goun
    Stanford University, Department of Chemistry Stanford, CA 94305, USA
    Chembiochem 7:1497-515. 2006
  2. ncbi request reprint Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:5299-302. 2006
    ..The resulting new analogs exhibit potent nanomolar or picomolar affinity to protein kinase C (PKC), comparable to or better than that found for bryostatin...
  3. pmc Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
    Elena A Dubikovskaya
    Department of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305 5080, USA
    Proc Natl Acad Sci U S A 105:12128-33. 2008
    ....
  4. pmc "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo
    Brian A DeChristopher
    Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, CA 94305 5080
    Oncotarget 3:58-66. 2012
    ..We provide the first in vivo validation that the bryostatin analog, picolog, is a potential therapeutic agent for the treatment of cancer and other diseases...
  5. ncbi request reprint Toward the ideal synthesis and molecular function through synthesis-informed design
    Paul A Wender
    Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, CA 94305, USA
    Nat Prod Rep 31:433-40. 2014
    ....
  6. doi request reprint Rhodium dinaphthocyclooctatetraene complexes: synthesis, characterization and catalytic activity in [5+2] cycloadditions
    Paul A Wender
    Department of Chemistry, Stanford University, CA 94305 5080, USA
    Angew Chem Int Ed Engl 51:2736-40. 2012
    ..dnCOT complexation with Rh(I) gives [Rh(dnCOT)(MeCN)(2)]SbF(6), an excellent catalyst for [5+2] cycloadditions of vinylcyclopropanes and π-systems with impressive functional group compatibility...
  7. ncbi request reprint Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:1893-6. 2006
    ..This analog exhibits potent, single-digit nanomolar affinity to PKC and selectively translocates novel PKC isozymes...
  8. ncbi request reprint Total synthesis and biological evaluation of 11-desmethyllaulimalide, a highly potent simplified laulimalide analogue
    Paul A Wender
    Departments of Chemistry and Molecular Pharmacology, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:1507-10. 2006
    ..This new lead retains the anticancer function of laulimalide...
  9. ncbi request reprint Metal-catalyzed [2+2+1] cycloadditions of 1,3-dienes, allenes, and CO
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305 5080, USA
    Angew Chem Int Ed Engl 45:2459-62. 2006
  10. ncbi request reprint Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305, USA
    Curr Drug Discov Technol 1:1-11. 2004
    ....
  11. ncbi request reprint Isolation, structure determination, and anti-cancer activity of apoptolidin D
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 9:691-4. 2007
    ..Its equilibration with isoapoptolidin D and characterization of the latter are also described. [structure: see text]...
  12. ncbi request reprint Dendrimeric molecular transporters: synthesis and evaluation of tunable polyguanidino dendrimers that facilitate cellular uptake
    Paul A Wender
    Department of Chemistry and Department of Molecular Pharmacology, Stanford University, California 94305 5080, USA
    Org Lett 7:4815-8. 2005
    ..While the dendrimers varied significantly in their ability to enter a human lymphocyte cell line, the best transporters out-performed an oligoarginine reference standard...
  13. pmc Apoptolidins B and C: isolation, structure determination, and biological activity
    Paul A Wender
    Department of Chemistry, Stanford University, California 94305 5080, USA
    Org Lett 7:3025-8. 2005
    ..These new agents are found to have antiproliferative activity on par with or better than apoptolidin itself in an assay with H292 lung cancer cells...
  14. ncbi request reprint Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs
    Paul A Wender
    Department of Chemistry, Stanford University, California 94305 5080, USA
    Org Lett 7:1995-8. 2005
    ..All three analogues exhibit potent, single-digit nanomolar affinity to protein kinase C...
  15. ncbi request reprint RhI-catalyzed C-C bond activation: seven-membered ring synthesis by a [6+1] carbonylative ring-expansion reaction of allenylcyclobutanes
    Paul A Wender
    Department of Chemistry, Department of Molecular Pharmacology, Stanford University, Stanford, CA 94305 5080, USA
    Angew Chem Int Ed Engl 45:3957-60. 2006
  16. pmc The design of guanidinium-rich transporters and their internalization mechanisms
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305, USA
    Adv Drug Deliv Rev 60:452-72. 2008
    ..Some GRT drug conjugates have been advanced into clinical trials. This review will provide an overview of recent work pertinent to the design and mechanism of uptake of GRTs...
  17. ncbi request reprint Cyclopentadienone synthesis by rhodium(I)-catalyzed [3 + 2] cycloaddition reactions of cyclopropenones and alkynes
    Paul A Wender
    Departments of Chemistry and of Molecular Pharmacology, Stanford University, Stanford, CA 94305 5080, USA
    J Am Chem Soc 128:14814-5. 2006
    ..The reaction is readily scalable to produce gram quantities of cycloadduct and provides a unique and versatile route to CPDs that would be otherwise difficult to obtain...
  18. ncbi request reprint Studies on oxidopyrylium [5+2] cycloadditions: toward a general synthetic route to the C12-hydroxydaphnetoxins
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:5373-6. 2006
    ..Depending on the choice of protecting groups and solvent, the oxidopyrylium-alkene [5+2] cycloaddition originating from A provides cycloadduct diastereomer B or C with good to excellent selectivity...
  19. ncbi request reprint Synthesis and PKC binding of a new class of a-ring diversifiable bryostatin analogues utilizing a double asymmetric hydrogenation and cross-coupling strategy
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:4581-4. 2006
    ..An aryl bromide diversification site is incorporated allowing access to systematically varied analogues. The new analogues all exhibit potent, nanomolar affinity to PKC...
  20. ncbi request reprint Pharmacophore mapping in the laulimalide series: total synthesis of a vinylogue for a late-stage metathesis diversification strategy
    Paul A Wender
    Departments of Chemistry and Molecular Pharmacology, Stanford University, Stanford, CA 94305 5080, USA
    Org Lett 8:4105-8. 2006
    ..This step-economical strategy enables the rapid synthesis of new analogues using alkenes as an inexpensive, abundantly available diversification feedstock...
  21. pmc Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305 5080, USA
    Proc Natl Acad Sci U S A 104:10340-5. 2007
    ....
  22. ncbi request reprint Nickel(0)-catalyzed [2 + 2 + 2 + 2] cycloadditions of terminal diynes for the synthesis of substituted cyclooctatetraenes
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305 5080, USA
    J Am Chem Soc 129:13402-3. 2007
  23. ncbi request reprint Function-oriented synthesis: studies aimed at the synthesis and mode of action of 1alpha-alkyldaphnane analogues
    Paul A Wender
    Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 9:1829-32. 2007
    ..A completely diastereoselective palladium-catalyzed enyne cyclization was then employed to establish the A-ring with a C1 appendage...
  24. ncbi request reprint Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 7:1177-80. 2005
    ..The use of this site in a late-stage diversification strategy has enabled the facile synthesis of a variety of new C20 analogs, all of which retain nanomolar affinity for PKC, in agreement with our pharmacophore hypothesis...
  25. pmc Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV
    Paul A Wender
    Department of Chemistry, Stanford University, 337 Campus Drive, Stanford, CA 94305, USA
    Science 320:649-52. 2008
    ..This synthesis reliably supplies gram quantities of the therapeutically promising natural products, hitherto available only in low and variable amounts from natural sources, and opens access to a variety of new analogs...
  26. pmc Total synthesis of bryostatin 9
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 133:9228-31. 2011
    ..At 25 linear and 42 total steps, this is currently the most concise and convergent synthesis of a potent bryostatin...
  27. ncbi request reprint Facile synthetic access to and biological evaluation of the macrocyclic core of apoptolidin
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305 5080, USA
    Org Lett 5:2299-302. 2003
    ..The ability of compounds derived from this cleavage to inhibit mitochondrial F(0)F(1)-ATPase is reported. [structure: see text]..
  28. ncbi request reprint Asymmetric catalysis of the [5 + 2] cycloaddition reaction of vinylcyclopropanes and pi-systems
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    J Am Chem Soc 128:6302-3. 2006
    ..A predictive model for the selectivity is also presented...
  29. pmc Gateway synthesis of daphnane congeners and their protein kinase C affinities and cell-growth activities
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    Nat Chem 3:615-9. 2011
    ..The natural product and a novel non-natural analogue exhibited significant potency, but the epimeric epoxide was essentially inactive...
  30. ncbi request reprint Isoapoptolidin: structure and activity of the ring-expanded isomer of apoptolidin
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 4:3819-22. 2002
    ..Isoapoptolidin's ability to inhibit mitochondrial F0F1-ATPase is over 10-fold less than that of apoptolidin...
  31. ncbi request reprint Toward a structure-activity relationship for apoptolidin: selective functionalization of the hydroxyl group array
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California, 94305 5080, USA
    Org Lett 5:487-90. 2003
    ..The syntheses of these derivatives and their ability to inhibit F(0)F(1)-ATPase are reported...
  32. ncbi request reprint The practical synthesis of a novel and highly potent analogue of bryostatin
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 124:13648-9. 2002
    ..Macrocycle 1 can be generated in clinically required amounts by chemical synthesis in only 19 steps (LLS) and represents a new clinical lead for the treatment of cancer...
  33. ncbi request reprint Oligocarbamate molecular transporters: design, synthesis, and biological evaluation of a new class of transporters for drug delivery
    Paul A Wender
    Department of Chemistry, Stanford University, California 94305 5080, USA
    J Am Chem Soc 124:13382-3. 2002
    ..Significantly, this new family of transporters also enables uptake into the formidable skin barrier of a probe molecule that by itself does not penetrate skin...
  34. ncbi request reprint Total synthesis of (-)-laulimalide
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 124:4956-7. 2002
    ..Laulimalide was synthesized in 25 steps (longest linear; 36 overall) in 3.5% overall yield, providing a uniquely short and efficient route to 1 and its analogues...
  35. pmc Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 108:6721-6. 2011
    ..These and related studies provide the basic information needed for the design of simplified and thus synthetically more accessible functional analogs that target PKC isoforms, major targets of therapeutic interest...
  36. ncbi request reprint Synthesis and biological evaluation of (-)-laulimalide analogues
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    Org Lett 5:3507-9. 2003
    ..Significantly, like laulimalide, these analogues are poor substrates for the drug transport protein P-glycoprotein (Pgp) and are thus effective against Taxol-resistant cell lines...
  37. ncbi request reprint A new synthetic approach to the C ring of known as well as novel bryostatin analogues
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 5:4549-52. 2003
    ..The convergent approach, illustrated above, requires fewer steps and offers greater flexibility in rapidly accessing diverse C ring analogues...
  38. doi request reprint Highly efficient, facile, room temperature intermolecular [5 + 2] cycloadditions catalyzed by cationic rhodium(I): one step to cycloheptenes and their libraries
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 12:1604-7. 2010
    ..The efficacy and selectivity of this catalyst are also shown in a novel diversification strategy, affording a cycloadduct library in one step from nine commercially available components...
  39. pmc Apoptolidins E and F, new glycosylated macrolactones isolated from Nocardiopsis sp
    Paul A Wender
    Department of Chemistry and Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 11:5474-7. 2009
    ..and their structures assigned. Lacking the C16 and C20 oxygens of apoptolidin A (1), these macrolides are also the first members of this family to display a 4-O-methyl-l-rhamnose at C9 rather than a 6-deoxy-4-O-methyl-l-glucose...
  40. doi request reprint Cyclocarboamination of alkynes with aziridines: synthesis of 2,3-dihydropyrroles by a catalyzed formal [3 + 2] cycloaddition
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 131:7528-9. 2009
    ..The reaction provides a wide range of polysubstituted dihydropyrroles in a highly regioselective manner, is scalable, proceeds under mild reaction conditions, and uses low catalyst loadings...
  41. ncbi request reprint Late-stage intermolecular CH activation for lead diversification: a highly chemoselective oxyfunctionalization of the C-9 position of potent bryostatin analogues
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 8050, USA
    Org Lett 7:79-82. 2005
    ..Complete selectivity for C-9 hydroxylation was restored upon acylation of the C-26 secondary alcohol...
  42. pmc Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy
    Paul A Wender
    Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 130:6658-9. 2008
    ..These tetrahydropyranyl B-ring analogues are among our most potent and efficacious analogues to date, exhibiting nanomolar and picomolar activities in protein kinase C affinity assays as well as in cellular antiproliferation assays...
  43. pmc Correlation of F0F1-ATPase inhibition and antiproliferative activity of apoptolidin analogues
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 8:589-92. 2006
    ..Potent F(0)F(1)-ATPase inhibition was not a sufficient determinant of antiproliferative activity for several analogues, suggesting the existence of a secondary biological target or more complex mode of action for apoptolidin...
  44. pmc The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity
    Paul A Wender
    Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 10:3331-4. 2008
    ..Several analogs exhibit single-digit nanomolar affinity to PKC and display superior activity compared to bryostatin against the leukemia cell line K562...
  45. ncbi request reprint Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP
    Jeremy L Baryza
    Department of Chemistry, Stanford University, Stanford, CA 94305, USA
    Chem Biol 11:1261-7. 2004
    ....
  46. ncbi request reprint Function-oriented synthesis, step economy, and drug design
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Acc Chem Res 41:40-9. 2008
    ..This approach enables the development of synthetically innovative strategies while targeting therapeutically novel structures...
  47. ncbi request reprint Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells
    Jonathan B Rothbard
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    J Am Chem Soc 126:9506-7. 2004
    ..The complex dissociates on the inner leaf of the membrane, and the transporter enters the cytosol. This hypothesis does not preclude uptake by other mechanisms, including endocytosis, which is likely to dominate with large cargos...
  48. pmc Oligocarbonate molecular transporters: oligomerization-based syntheses and cell-penetrating studies
    Christina B Cooley
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 131:16401-3. 2009
    ....
  49. ncbi request reprint Releasable luciferin-transporter conjugates: tools for the real-time analysis of cellular uptake and release
    Lisa R Jones
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    J Am Chem Soc 128:6526-7. 2006
    ..The process provides a method to assay uptake and release of free luciferin as a function of variations in the releasable linker and in the transporter...
  50. pmc An approach to the site-selective diversification of apoptolidin A with peptide-based catalysts
    Chad A Lewis
    Department of Chemistry, Yale University, 225 Prospect Street, New Haven, Connecticut 06520 8107, USA
    J Nat Prod 72:1864-9. 2009
    ..Biological evaluation of the new apoptolidin analogues was then conducted using growth inhibition assays based on the H292 human lung carcinoma cell line. The new analogues exhibited activities comparable to apoptolidin A...
  51. ncbi request reprint Gene transfer via reversible plasmid condensation with cysteine-flanked, internally spaced arginine-rich peptides
    Zurab Siprashvili
    VA Palo Alto Healthcare System, Palo Alto, CA 94305, USA
    Hum Gene Ther 14:1225-33. 2003
    ..Thus, cysteine-flanked, internally spaced arginine-rich (CFIS-R) peptides represent a new approach to efficient nonviral plasmid delivery using rationally designed protein transduction domains...
  52. ncbi request reprint Guanidinium rich peptide transporters and drug delivery
    Lee R Wright
    Department of Chemistry, Stanford University, Stanford, California 95304, USA
    Curr Protein Pept Sci 4:105-24. 2003
    ..Lead conjugates in this area are currently in clinical trials...
  53. ncbi request reprint A concise, selective synthesis of the polyketide spacer domain of a potent bryostatin analogue
    Paul A Wender
    Department of Chemistry, Stanford University, Stanford, California 94305 5080, USA
    Org Lett 5:277-9. 2003
    ..The spacer domain 1 is obtained in 10 steps with a 25% overall yield and is readily incorporated into the synthesis of 2...
  54. ncbi request reprint Actin is the primary cellular receptor of bistramide A
    Alexander V Statsuk
    Department of Chemistry, University of Chicago, Chicago, Illinois 60637, USA
    Nat Chem Biol 1:383-8. 2005
    ....
  55. ncbi request reprint Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation
    Elena A Goun
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    Bioconjug Chem 17:787-96. 2006
    ..These APTD peptide-based molecules may facilitate targeted delivery of therapeutics or imaging agents to PSA-expressing prostate cancers...
  56. ncbi request reprint Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells
    Jonathan B Rothbard
    Department of Chemistry, Stanford University, Stanford CA 94305, USA
    Adv Drug Deliv Rev 57:495-504. 2005
    ..This mechanism could also be involved in the translocation of guanidinium-rich molecules that are endocytosed due to their size or the conditions of the assay, across the endosomal membrane...
  57. ncbi request reprint Photoinduced cleavage of DNA by bromofluoroacetophenone-pyrrolecarboxamide conjugates
    Paul A Wender
    Department of Chemistry, Stanford University, CA 94305, USA
    Bioorg Med Chem Lett 13:1763-6. 2003
    ..The DNA cleaving activities of 2'-bromo-4'-fluoroacetophenone derivatives were larger than those of 4'-bromo-2'-fluoroacetophenone derivatives...
  58. ncbi request reprint Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into Mammalian cells
    Nadine Wong Shi Kam
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    J Am Chem Soc 126:6850-1. 2004
    ..The biocompatibility and unique physical, electrical, optical, and mechanical properties of nanotubes provide the basis for new classes of materials for drug, protein, and gene delivery applications...
  59. ncbi request reprint Arginine-based molecular transporters: the synthesis and chemical evaluation of releasable taxol-transporter conjugates
    Thorsten A Kirschberg
    CellGate, Inc, 552 Del Rey Avenue, Sunnyvale, California 95085, USA
    Org Lett 5:3459-62. 2003
    ..The resultant taxol-transporter conjugates are highly water soluble and release free taxol with half-lives of minutes to hours depending on the pH and the linker structure...
  60. ncbi request reprint Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake
    Jonathan B Rothbard
    CellGate Inc, 552 Del Rey Avenue, Sunnyvale, California 94085, USA
    J Med Chem 45:3612-8. 2002
    ..This study led to the identification of a new series of highly efficient molecular transporters...
  61. pmc Microtubule-stabilizing agents based on designed laulimalide analogues
    Susan L Mooberry
    Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, 7620 Northwest Loop 410, San Antonio, TX 78227, USA
    Proc Natl Acad Sci U S A 101:8803-8. 2004
    ..In summary, analogues of laulimalide designed to minimize or eliminate its intrinsic instability have been synthesized, and some have been found to retain the unique biological activities of laulimalide...
  62. ncbi request reprint Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol
    Erin A Clark
    Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, 7620 NW Loop 410, San Antonio, Texas 78227, USA
    Mol Pharm 3:457-67. 2006
    ..These important findings suggest that specific combinations of microtubule-targeting agents should be considered for clinical utilities as they have excellent potential to improve clinical response...
  63. ncbi request reprint Synthetic bryostatin analogues activate the RasGRP1 signaling pathway
    James C Stone
    Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
    J Med Chem 47:6638-44. 2004
    ..In addition to sharing potential anticancer properties with bryostatin 1, compounds 1 and 2 might be clinically useful as modulators of the immune system...
  64. ncbi request reprint Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells
    Caitlin Hammond
    Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women s College Health Sciences Center, 2075 Bayview Avenue, Toronto, Canada M4N 3M5
    J Immunother 28:28-39. 2005
    ..The observation that CLL cells can acquire features of dendritic cells that promote type 1 immunity may find clinical application in immunotherapeutic strategies for this disease...
  65. doi request reprint Substituent effects, reactant preorganization, and ligand exchange control the reactivity in Rh(I)-catalyzed (5+2) cycloadditions between vinylcyclopropanes and alkynes
    Peng Liu
    Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095 1569, USA
    Angew Chem Int Ed Engl 47:3939-41. 2008
  66. ncbi request reprint A computationally designed Rh(I)-catalyzed two-component [5+2+1] cycloaddition of ene-vinylcyclopropanes and CO for the synthesis of cyclooctenones
    Yuanyuan Wang
    Beijing National Laboratory for Molecular Sciences BNLMS, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry, Peking University, Beijing 100871, China
    J Am Chem Soc 129:10060-1. 2007
  67. doi request reprint Origins of differences in reactivities of alkenes, alkynes, and allenes in [Rh(CO)2Cl]2-catalyzed (5 + 2) cycloaddition reactions with vinylcyclopropanes
    Zhi Xiang Yu
    Key Laboratory of Bioorganic Chemistry and Molecular Engineering of the Ministry of Education, College of Chemistry, Peking University, Beijing 100871, PR China
    J Am Chem Soc 130:2378-9. 2008

Research Grants49

  1. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2006
    ..abstract_text> ..
  2. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2001
    ..Overall, this program is expected to be of significant value in chemistry, biology, and medicine. ..
  3. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 1990
    ..A new enolate chemistry will be developed in connection with a general approach to cannabinoid synthesis...
  4. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 1990
    ..Computer modelling and bioassays will be performed in conjunction with these and related projects in order to establish the structural basis for the potent biological activities of the promoters and PKC activators...
  5. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2003
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  6. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 1991
    ..Computer modelling and bioassays will be performed in conjunction with these and related projects in order to establish the structural basis for the potent biological activities of the promoters and PKC activators...
  7. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2007
    ....
  8. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2009
    ..abstract_text> ..
  9. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2000
    ..Overall, this research program is expected-to be of significant value in chemistry, biology, and medicine. ..
  10. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2007
    ..abstract_text> ..
  11. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    PAUL ANTHONY WENDER; Fiscal Year: 2010
    ..The project provides for the creation of fundamental knowledge of broad potential utility and at the same time new approaches and agents to address unmet clinical needs in cancer, HIV/AIDS and other diseases. ..
  12. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2002
    ..Overall, this program is expected to be of significant value in chemistry, biology, and medicine. ..
  13. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2002
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  14. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2005
    ..abstract_text> ..
  15. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2000
    ..Overall, this program is expected to be of significant value in chemistry, biology, and medicine. ..
  16. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 1993
    ..A final project entails completion of studies on the synthesis of aplysiatoxin. Overall, this research program is expected to be of significant value in chemistry, biology, and medicine...
  17. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 1992
    ..Computer modelling and bioassays will be performed in conjunction with these and related projects in order to establish the structural basis for the potent biological activities of the promoters and PKC activators...
  18. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 1999
    ..Overall, this research program is expected-to be of significant value in chemistry, biology, and medicine. ..
  19. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2004
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  20. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2001
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  21. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2004
    ..Overall, this program is expected to be of significant value in chemistry, biology, and medicine. ..
  22. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 1992
    ..A final project entails completion of studies on the synthesis of aplysiatoxin. Overall, this research program is expected to be of significant value in chemistry, biology, and medicine...
  23. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 1991
    ..A final project entails completion of studies on the synthesis of aplysiatoxin. Overall, this research program is expected to be of significant value in chemistry, biology, and medicine...
  24. SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENT
    Paul Wender; Fiscal Year: 2005
    ..Overall, this research program is expected to be of significant value in chemistry, biology, and medicine. ..
  25. SYNTHETIC STUDIES ON TUMOR PROMOTERS AND INHIBITORS
    Paul Wender; Fiscal Year: 2003
    ..Overall, this program is expected to be of significant value in chemistry, biology, and medicine. ..